Antonin De Fougerolles

Graduated from:

McGill University
Harvard University (USA)

USPTO Granted Patents = 91 (Patent Applications = 36)

CIPO Patents = 4 (Patent Applications = 8)

EPO Patents = 20 (Patent Applications = 27)

Average Co-Inventor Count = 3.9

ph-index = 33

Forward Citations = 3,868(Granted Patents)

Forward Citations (Not Self Cited) = 3,687(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Cambridge, MA (US) (2011 - 2020)
Waterloo, BE (2015 - 2021)
Brookline, MA (US) (2002 - 2024)

Company Filing History:

29 out of 34

Moderna Therapeutics, Inc.

patents

26 out of 444

Alnylam Pharmaceuticals, Inc.

US Government As Represented by the Secretary of the Army

patents

7. 4 out of 96

Arrowhead Pharmaceuticals, Inc.

Imperial College of Science, Technology and Medicine

patents

10. 1 out of 18

Arrowhead Research Corporation

patents

11. 1 out of 3

The United States of America As Represented by the Army

patents

12. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

Lipid Formulated Compositions

Engineered Nucleic Acids

Modified Polynucleotides

Beta-ENaC-Related Diseases

In Vivo Protein Production

Nucleic Acid Formulation

Oncology-Related Proteins

RNA Synthesis Enzymes

Gene Expression Inhibition

Biologics Production

Secreted Proteins

Protein Deficiency Treatments

91 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11884919 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene (2024-01-30),

2. 11149273 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene (2021-10-19),

3. 10898574 - Delivery and formulation of engineered nucleic acids (2021-01-26),

4. 10550391 - Organic compositions to treat beta-ENaC-related diseases (2020-02-04),

5. 10493167 - In vivo production of proteins (2019-12-03),

6. 10472628 - Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene (2019-11-12),

7. 10258698 - Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions (2019-04-16),

8. 10081811 - Organic compositions to treat Beta-ENaC-related diseases (2018-09-25),

9. 9902774 - Method for the treatment of inflammatory disorders (2018-02-27),

10. 9868950 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene (2018-01-16),

11. 9828416 - Modified polynucleotides for the production of secreted proteins (2017-11-28),

12. 9827332 - Modified polynucleotides for the production of proteins (2017-11-28),

13. 9814760 - Modified polynucleotides for the production of biologics and proteins associated with human disease (2017-11-14),

14. 9782462 - Modified polynucleotides for the production of proteins associated with human disease (2017-10-10),

15. 9752152 - Organic compositions to treat beta-ENaC-related diseases (2017-09-05),

Title: Inventor Antonin de Fougerolles

Introduction: Antonin de Fougerolles is a renowned inventor based in Brookline, MA (US) known for his groundbreaking contributions to various fields.

Latest Patents: Antonin de Fougerolles holds several patents in the areas of biotechnology, renewable energy, and medical devices, showcasing his diverse range of expertise.

Career Highlights: With a background in biochemistry and engineering, Antonin de Fougerolles has led numerous research projects that have resulted in innovative solutions and technologies that have made a significant impact in their respective industries.

Collaborations: Throughout his career, Antonin de Fougerolles has collaborated with leading universities, research institutions, and companies to further develop and commercialize his inventions, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Antonin de Fougerolles continues to be a driving force in the world of innovation, with his passion for creating cutting-edge solutions that address complex challenges setting him apart as a visionary inventor.

This text is generated by artificial intelligence and may not be accurate.